Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta- analysis

Circulation

Volumn 98, Issue 23, 1998, Pages 2520-2526

  Brattström, Lars ^a   Wilcken, David E L ^b   Öhrvik, John ^c   Brudin, Lars ^a  

^a KALMAR COUNTY HOSPITAL   (Sweden)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Coronary disease; Homocysteine; Methylenetetrahydrofolate reductase; Risk factors

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ARTICLE; CONTROLLED STUDY; CORONARY RISK; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR DISEASE;

EID: 0032497941     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.23.2520     Document Type: Article

References (55)

1. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, ed. Atherosclerotic Cardiovascular Disease, Hemostasis and Endothelial Function. New York, NY: Marcel Dekker Inc; 1992:183-236.
2. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274: 1049-1057.
3. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 7th ed. New York, NY: McGraw-Hill; 1995:1279-1327.
4. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest. 1976;57: 1079-1082.
5. Brattström LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia: a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke. 1984;15:1012-1015.
6. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PWC. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-715.
7. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
8. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg I. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-291.
9. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary artery disease. Int J Epidemiol. 1995;24:704-709.
10. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-age British men. Lancet. 1995;346:1395-1398.
11. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
12. Graham IM, Daly LE, Refsum H, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Lúis AC, Parrot-Roulaud FM, Soon Tan K, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G, for The European Concerted Action Project. Plasma homocysteine as a risk factor for vascular disease. JAMA. 1997;277:1775-1781.
13. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988;43:414-421.
14. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
15. van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbels FJM, Eskes TKAB, van den Heuvel LP, Mariman ECM, den Heyer M, Rozen R, Blom HJ. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995;346:1070-1071.
16. Jacques PF, Bostom AG, Wíllíams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.
17. Harmon DL, Woodside JV, Yarnell JWG, McMaster D, Young IS, McCrum EE, Gey KF, Whitehead AS, Evans AE. The common "thermolabile" variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. Q J Med. 1996;89:571-577.
18. Kluijtmans LAJ, van den Heuvel PWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetics analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
19. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction: a case-control study. Circulation. 1996;94:1812-1814.
20. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow R, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996;94:2410-2416.
21. Deloughery TG, Evans A, Sadeghi A, McWilliams J, Henner WD, Taylor LM, Press RD. Common mutation in methylenetetrahydrofolate reductase: correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 1996;94:3074-3078.
22. Verhoef P, Kok FJ. Kluijtmans LAJ, Blom HJ, Refsum H, Ueland PM, Kruyssen HACM. The 677CT mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk for coronary atherosclerotic disease. Atherosclerosis. 1997;132: 105-113.
23. Kluijtmans LAJ, Kastelein JJP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG, Jukema JW, Vandenheuvel LPWJ, Trijbels FJM, Boerma GJM, Verheugt FWA, Willems F, Blom HJ. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997;96:2573-2577.
24. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, Genest J, Rozen R. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:569-573.
25. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, Psaty BM, Longstreth WT Jr, Koepsell TD, Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 1997;96:412-417.
26. 223Val MTHFR) in patients with inherited thrombophilic coagulation defects. Arterioscler Thromb Vasc Biol. 1997;17:2924-2929.
27. Gallagher PM, Meleady R, Shields DC, Soon Tan K, McMaster D, Rozen R, Evans A, Graham IM, Whitehead AS. Homocysteine and risk of premature coronary heart disease: evidence for a common gene mutation. Circulation. 1996;94:2154-2158.
28. Adams M, Smith PD, Martin D, Thomson JR, Lodwick D, Samani NJ. Genetic analysis of thermolabile memylenetetrahydrofolate reductase as a risk factor for myocardial infarction. Q J Med. 1996;89:437-444.
29. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis. 1996;121:293-294.
30. 677T mutation. Arterioscler Thromb Vasc Biol. 1996;16: 878-882.
31. de Franchis R, Mancini FP, D'Angelo A, Sebastio G, Fermo I, de Stefano V. Elevated total plasma homocysteine and 677C→T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet. 1996;59:262-264.
32. Narang R, Callaghan G, Haider AW, Davies GJ, Tuddenham EGD. Methylenetetrahydrofolate reductase mutation and coronary artery disease. Circulation. 1996;94:2322-2323.
33. Brulhart MC, Dussoix P, Ruiz J, Passa P, Froguel P, James RW. The (Ala-Val) mutation of methylenetetrahydrofolate reductase as a genetic risk factor for vascular disease in non-insulin-dependent diabetic patients. Am J Hum Genet. 1997;60:228-229.
34. van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997;95:21-23.
35. Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis. 1997;128:107-112.
36. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S. Yazaki Y. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997;95:2032-2036.
37. Verhoef P, Rimm EB, Hunter DJ, Chen J, Willett WC, Kelsey K, Stampfer MJ. Methylenetetrahydrofolate reductase polymorphism, diet, and risk of coronary heart disease among men. 16th International Congress of Nutrition. July 27-August 1, 1997, Montreal, Canada. Abstract PW3.12.
38. Tosetto A, Míssíaglía E, Frezzato M, Rodeghiero F, the VITA Project. C677T mutation in the methylene-tetrahydrofolate reductase gene and risk of venous thromboembolism. Br J Haematol. 1997;97:804-806.
39. Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, Block PC, Holzgang CR, Anderson PH, Seltzer D, Upson B, Lin QR. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol. 1997;17:1157-1162.
40. Markus H, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke. 1997; 28:1739-1743.
41. Salden A, Keeney S, Hay CRM, Cumming AM. The C677T MTHFR variant and the risk of venous thrombosis. Br J Haematol. 1997;99:464-472.
42. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677→Val in the methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost. 1997;77:818-821.
43. Anderson JL, King GJ, Thomson MJ, Todd M, Bair TL, Muhlestein JB, Carlquist JF. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 1997;30:1206-1211.
44. Sandercock P. The odds ratio: a useful tool in neurosciences. J Neurol Neurosurg Psychiatry. 1989;52:817-820.
45. Agresti A. An Introduction to Categorical Data Analysis. New York, NY: John Wiley & Sons; 1996:63-64.
46. Guttormsen AB, Ueland PM, Nesthus I, Nygård O, Schneede J, Vollset SE, the Hordaland homocysteine study. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/L). J Clin Invest. 1996;98:2174-2183.
47. Brattström L, Zhang Y, Hurtig M, Refsum H, Östensson S, Fransson L, Jonés K, Landgren F, Brudin L, Ueland PM. A common methylenetetrahydrofolate reductase gene mutation (C677T/MTHFR) and longevity. Atherosclerosis. In press.
48. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost. 1997; 78:523-526.
49. Nygård O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvåle G, the Hordaland Homocysteine Study. Total plasma homocysteine and cardiovascular risk profile. JAMA. 1995;274: 1526-1533.
50. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int. 1997;52:495-502.
51. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Lab Invest. 1996;56:41-46.
52. Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med. 1994;236:633-641.
53. Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A. Hyperhomocysteinemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 1992;22:214-221.
54. Mudd HS, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Gröbe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet. 1985;37:1-31.
55. Wilcken DEL, Wilcken B. The natural history of vascular disease in homocystinuria and the effect of treatment. J Inherit Metab Dis. 1997; 20:295-300.